Cisplatin and Alternating Temozolomide in Recurrent High-Grade Gliomas: Efficacy and the Role of Tumor-Infiltrating Lymphocytes in a Phase II Clinical Trial
Yu Yao(Qinghai University), Chunxia Ji(Shanghai Public Health Clinical Center), Haixia Cheng(Fudan University), Di Chen(Fudan University), Dikang Chen(Fudan University), Zhenyu Zhang(Dalian Medical University), Ying Qi(Kunming University), Jianbo Wen(Fudan University), Chao Tang(North Sichuan Medical University), Lingchao Chen(Allen Institute for Brain Science), Yuyuan Wang(University of Wisconsin–Madison)
Cited by 2
Related Papers
CGCG clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2016|650
Clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2020|482
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
|The Lancet Oncology|2016|374
Temozolomide-associated hypermutation in gliomas
|Neuro-Oncology|2018|227
Adult IDH wild-type lower-grade gliomas should be further stratified
|Neuro-Oncology|2017|222